Your browser doesn't support javascript.
loading
Polygenic Parkinson's Disease Genetic Risk Score as Risk Modifier of Parkinsonism in Gaucher Disease.
Blauwendraat, Cornelis; Tayebi, Nahid; Woo, Elizabeth Geena; Lopez, Grisel; Fierro, Luca; Toffoli, Marco; Limbachiya, Naomi; Hughes, Derralynn; Pitz, Vanessa; Patel, Dhairya; Vitale, Dan; Koretsky, Mathew J; Hernandez, Dena; Real, Raquel; Alcalay, Roy N; Nalls, Mike A; Morris, Huw R; Schapira, Anthony H V; Balwani, Manisha; Sidransky, Ellen.
  • Blauwendraat C; Integrative Neurogenomics Unit, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA.
  • Tayebi N; Center for Alzheimer's and Related Dementias, National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.
  • Woo EG; Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Lopez G; Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Fierro L; Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Toffoli M; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Limbachiya N; Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.
  • Hughes D; Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.
  • Pitz V; Lysosomal Storage Diseases Unit, Royal Free London Hospital NHS Foundation Trust, and Department of Hematology, University College London, London, United Kingdom.
  • Patel D; Integrative Neurogenomics Unit, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA.
  • Vitale D; Integrative Neurogenomics Unit, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA.
  • Koretsky MJ; Center for Alzheimer's and Related Dementias, National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.
  • Hernandez D; Data Tecnica International, Washington, District of Columbia, USA.
  • Real R; Center for Alzheimer's and Related Dementias, National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.
  • Alcalay RN; Molecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA.
  • Nalls MA; Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.
  • Morris HR; Department of Neurology, Columbia University Irving Medical Center, New York, New York, USA.
  • Schapira AHV; Neurological Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • Balwani M; Center for Alzheimer's and Related Dementias, National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.
  • Sidransky E; Data Tecnica International, Washington, District of Columbia, USA.
Mov Disord ; 38(5): 899-903, 2023 05.
Article en En | MEDLINE | ID: mdl-36869417
ABSTRACT

BACKGROUND:

Biallelic pathogenic variants in GBA1 are the cause of Gaucher disease (GD) type 1 (GD1), a lysosomal storage disorder resulting from deficient glucocerebrosidase. Heterozygous GBA1 variants are also a common genetic risk factor for Parkinson's disease (PD). GD manifests with considerable clinical heterogeneity and is also associated with an increased risk for PD.

OBJECTIVE:

The objective of this study was to investigate the contribution of PD risk variants to risk for PD in patients with GD1.

METHODS:

We studied 225 patients with GD1, including 199 without PD and 26 with PD. All cases were genotyped, and the genetic data were imputed using common pipelines.

RESULTS:

On average, patients with GD1 with PD have a significantly higher PD genetic risk score than those without PD (P = 0.021).

CONCLUSIONS:

Our results indicate that variants included in the PD genetic risk score were more frequent in patients with GD1 who developed PD, suggesting that common risk variants may affect underlying biological pathways. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / Trastornos Parkinsonianos / Enfermedad de Gaucher Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / Trastornos Parkinsonianos / Enfermedad de Gaucher Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article